Cetuximab + capecitabine + irinotecan (CCI) versus cetuximab + capecitabine + oxaliplatin (CCO) as first line therapy for patients with metastatic colorectal cancer (CRC): Preliminary results of a randomized phase II trial of the AIO CRC Study Group

Volker Heinemann(LMU Klinikum), Hermann Dietzfelbinger, Martina Stauch, Manfred Schulze, Nicolas Moosmann(Praxis für Hämatologie und Onkologie), Ludwig Fischer von Weikersthal(Praxis für Hämatologie und Onkologie), Joseph B. Weiss(University of North Carolina Health Care), U. Vehling-Kaiser(University of Applied Sciences Landshut), Daniel Oruzio(Praxis für Hämatologie und Onkologie)

Journal of Clinical Oncology

June 20, 2006

10.1200/jco.2006.24.18_suppl.3550

Cited by 11

Related Papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

|The Lancet|2019|2.6k

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

|The Lancet Oncology|2014|1.7k

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

|The Lancet|2013|1.5k

Prognostic and Predictive Relevance of Primary Tumor Location in Patients With <i>RAS </i>Wild-Type Metastatic Colorectal Cancer

|JAMA Oncology|2016|722

The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials

|European Journal of Cancer|2016|533